OR WAIT null SECS
Medidata and Cognizant Form Strategic Alliance to Make Digital Transformation Accessible for the Life Sciences
Turnkey solutions will accelerate and optimize operational aspects of a clinical trial by bringing together industry-leading life science software with world-class managed services
Life science organizations of all sizes and therapeutic areas can leverage enterprise-grade technology and expertise to drive their digital transformation
NEW YORK, February 11, 2019 -- Medidata (NASDAQ: MDSO) and Cognizant (NASDAQ: CTSH) have entered into a strategic alliance to offer life science clients comprehensive solutions that leverage the market’s leading cloud platform with world-class business and technology services. This provides pharmaceutical, biotech, medical device companies, contract research organizations (CROs), sites and investigators with digital capabilities to facilitate a fast start to clinical trials, simplify operational complexities and drive digital transformation.
As part of the multi-year agreement, Cognizant will develop and deliver a comprehensive set of managed services and solutions specific to Medidata’s platform. Cognizant’s expertise in business process, technology and digital services (including biostats, automation and help desks) will combine with solutions across the Medidata platform, such as Randomization and Trial Supply Management. This will create clinical capabilities as-a-service to help address the increasing complexities and global scale of clinical trials.
As an example of how Medidata is providing more choices for customers, Medidata Site Payments will seamlessly connect with Cognizant’s Shared Investigator Platform (SIP) -- the industry standard platform designed to improve the experience of investigators, sites and sponsors.
Clinical trials are becoming more complex to implement and conduct due to big data, AI and the desire for more targeted therapies. The professional services component of this alliance provides life science companies with technology and expertise to architect, implement and optimize studies.
“Most life science companies have stitched together multiple legacy solutions and are in dire need for a clinical refresh. This partnership allows us to offer and manage the most comprehensive platform and suite of services for our clients so that they can focus on the science rather than operational complexities,” said Bhaskar Sambasivan, senior vice president and global head of life sciences at Cognizant.
“This alliance exemplifies the power of Medidata’s technology combined with the expertise of the broadest and most advanced partner ecosystem, which we have built in life sciences,” said Tarek Sherif, chairman and chief executive officer, Medidata. “We are deepening our partnership with Cognizant to help customers around the globe fully realize the value of digital transformation.”
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 195 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.medidata.com.